Wegovy (semaglutide) is a new weight loss drug that was approved by the FDA in June 2021. It is a once-weekly injection that works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which reduces appetite and helps regulate blood sugar levels.

Compared to other weight loss drugs, Wegovy has shown to be more effective. In clinical trials, patients taking Wegovy lost an average of 15% of their body weight, which is significantly more than other weight loss drugs. For example, Ozempic (also a GLP-1 agonist) has been shown to help patients lose an average of 5-10% of their body weight [2].

Wegovy is also more convenient than other weight loss drugs. Unlike other drugs that require daily dosing, Wegovy is taken once a week, which may make it easier for patients to stick to their treatment plan.

However, like all drugs, Wegovy has potential side effects. In clinical trials, the most common side effects were gastrointestinal-related, such as nausea, diarrhea, and vomiting. There is also a risk of thyroid cancer, although this risk appears to be low [3].

In summary, Wegovy appears to be a more effective and convenient weight loss drug compared to other drugs on the market. However, patients should be aware of potential side effects and discuss the risks and benefits of the drug with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.drugs.com/medical-answers/mounjaro-wegovy-ozempic-compare-weight-loss-3570898/
[3] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/